

UCSF Helen Diller Family
Comprehensive
Cancer Center

Adult Cancers

Breast (32 trials)
Cutaneous (15 trials)
Gastrointestinal (15 trials)
Genitourinary (32 trials)
Gynecological (8 trials)
Head and Neck (10 trials)
Malignant Hematology (32 trials)
Multiple / Ill-Defined Disease Sites (18 trials)
Neurologic Oncology (9 trials)
Thoracic (14 trials)
Other Trials (86 trials)
Total Trials = 271

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Prevention					
227518	NCT04821141	Esserman, Laura	Randomized IIB Study of the Effect of Bazedoxifene plus Conjugated Estrogens on Breast Imaging and Tissue Biomarkers in Peri or Post-Menopausal Women at Increased Risk for Development of Breast Cancer	Prevention	anna.vertido@ucsf.edu
25756	NCT07121972	Chung, Maggie	Mirai-MRI: Multi-site Prospective Validation of AI Models for Breast Cancer Risk	Screening	Alya.Briceno@ucsf.edu
16752	NCT02620852	Esserman, Laura	The WISDOM Study (Women Informed to Screen Depending on Measures of Risk)	Screening	1-877-827-3222
Breast > Breast Cancer Treatment					
NRG-BR007	NCT04852887	Yoshida, Emi	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence score less than or equal to 18 Breast Cancer	Treatment	Bogdan.Eftimie@ucsf.edu
ALLIANCE-A012103	NCT05812807	Dixit, Niharika	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy	Treatment	1-877-827-3222
23992	NCT06177171	Munster, Pamela	A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; savannah.berkley@ucsf.edu
Breast > Symptom Management / Survivorship					
24807	NCT06633926	Dhruva, Anand	Integrative Approaches for Cancer Survivorship: A Multi-Site Feasibility and Acceptability Study (Aim 2)	Supportive Care	Patricia.Moran@ucsf.edu; peea.kimhassel@ucsf.edu
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	erin.vanblarigan@ucsf.edu
228014	NCT06055803	Beatty, Alexis	The Heart Health After Cancer Treatment (HEART-ACT): A pilot study of a multi-disciplinary health behavior intervention in people with a history of breast cancer to reduce heart disease risk after cancer treatment	Supportive Care	ivan.leung@ucsf.edu
238010	NCT06215469	Chien, Jo	Amma™ Portable Scalp Cooling System (PSCS) Study: A Post-Market Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss in Women Receiving Specific Chemotherapy Regimens for Early-Stage Breast Cancer	Supportive Care	1-877-827-3222
NRG-CC011	NCT05896189	Eftimie, Bogdan	Cognitive Training For Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial	Prevention	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Breast Cancer Treatment > Early Stage Breast Cancer					
237519	NCT05232916	Huppert, Laura	A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)	Prevention	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Surgery					
217510	NCT05020574	Piper, Merisa	Microbiome and Association with Implant Infections: Investigating the Impact of Antibiotics on the Gut and Breast Microbiomes Post-Mastectomy with Implant-Based Breast Reconstruction	Supportive Care	laura.barnes@ucsf.edu
Breast > Breast Cancer Treatment > Advanced Breast Cancer > ER+					
21758	NCT04862663	Chien, Jo	A Phase Ib/III, Open-Label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)	Treatment	Amy.Deluca@ucsf.edu
207513	NCT03990896	Huppert, Laura	Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: genotyping based clinical trial	Treatment	Amy.Deluca@ucsf.edu
24758	NCT06369285	Melisko, Michelle	A PHASE 2 STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER	Treatment	Amy.Deluca@ucsf.edu
25758	NCT06982521	Batra-Sharma, Hemali	A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor	Treatment	Amy.Deluca@ucsf.edu
21753	NCT04802759	Chien, Jo	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)	Treatment	Amy.Deluca@ucsf.edu
25755	NCT06760637	Melisko, Michelle	AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)	Treatment	Amy.Deluca@ucsf.edu
23756	NCT05508906	Chien, Jo	A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination with the CDK4/6 Inhibitor Ribociclib, with the PI3K Inhibitor Alpelisib, with the mTOR inhibitor Everolimus, or with CDK4 Inhibitor Atirmociclib in Adult Subjects with Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer	Treatment	Amy.Deluca@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Breast Cancer Treatment > Advanced Breast Cancer > HER2+					
24758	NCT06369285	Melisko, Michelle	A PHASE 2 STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Advanced Breast Cancer > Triple Negative					
237536	NCT06099769	Melisko, Michelle	A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER	Treatment	Amy.Deluca@ucsf.edu
23754	NCT05633654	Melisko, Michelle	A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy	Treatment	Amy.Deluca@ucsf.edu
187519	NCT03971409	Huppert, Laura	Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A multicenter, multi-arm Translational Breast Cancer Research Consortium study (TBCRC 047: InCITe) MASTER PROTOCOL	Treatment	Amy.Deluca@ucsf.edu
25754	NCT06841354	Huppert, Laura	A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)	Treatment	Amy.Deluca@ucsf.edu
207519	NCT04434040	Chien, Jo	A Single Arm Phase 2 Trial of Atezolizumab with Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)	Treatment	Amy.Deluca@ucsf.edu
207513	NCT03990896	Huppert, Laura	Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: genotyping based clinical trial	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Advanced Breast Cancer > Non-Specific					
247520	NCT06533826	Huppert, Laura	A Phase II Non-Comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients with Metastatic HER2-Negative (HER2low or HER2-0) Breast Cancer after Progression on Prior Antibody Drug Conjugate Therapy	Treatment	Amy.Deluca@ucsf.edu
Breast > Breast Cancer Treatment > Advanced Breast Cancer > Phase I					
21758	NCT04862663	Chien, Jo	A Phase Ib/III, Open-Label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)	Treatment	Amy.Deluca@ucsf.edu
25703	NCT06778863	Oh, David	GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Treatment	Christina.Chun@ucsf.edu; allyson.beaulieu@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive > Neoadjuvant					
097517	NCT01042379	Chien, Jo	I-SPY 2 TRIAL - Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2	Treatment	jayne.weisenstein@ucsf.edu
Breast > Breast Cancer Treatment > Early Stage Breast Cancer > In Situ > Neoadjuvant					
237522	NCT06075953	Jackson, Jordan	DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study	Treatment	lorraine.jiang@ucsf.edu
Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive > Adjuvant					
217519	NCT04893109	Batra-Sharma, Hemali	A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)	Treatment	Amy.Deluca@ucsf.edu
ALLIANCE-A012301	NCT06671912	DeBoer, Rebecca	LOTAM: A RANDOMIZED, PHASE III CLINICAL TRIAL OF LOW-DOSE TAMOXIFEN FOR SELECTED PATIENTS WITH MOLECULAR LOW-RISK EARLY-STAGE BREAST CANCER	Treatment	ivan.leung@ucsf.edu
247514	NCT06492616	Melisko, Michelle	Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence- A Global, Multicenter, Randomized, Open-label Phase 3 Study	Treatment	Amy.Deluca@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Cutaneous > Melanoma					
20863	NCT04598009	Tsai, Katy	A phase II study of binimetinib in combination with imatinib in patients with advanced KIT-mutant melanoma	Treatment	sonia.contrerasmartinez@ucsf.edu
25857	NCT06743126	Daud, Adil	A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)	Treatment	sonia.contrerasmartinez@ucsf.edu
248510	NCT06425926	Tsai, Katy	A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination with Anti-PD-1 in Advanced Solid Tumors	Treatment	sonia.contrerasmartinez@ucsf.edu
25853	NCT06961006	Daud, Adil	A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012)	Treatment	sonia.contrerasmartinez@ucsf.edu
25855	NCT05538130	Daud, Adil	A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS	Treatment	sonia.contrerasmartinez@ucsf.edu
24859	NCT06413680	Daud, Adil	A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES	Treatment	sonia.contrerasmartinez@ucsf.edu
24854	NCT06264180	Tsai, Katy	A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen	Treatment	sonia.contrerasmartinez@ucsf.edu
24858	NCT06246916	Tsai, Katy	A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA	Treatment	sonia.contrerasmartinez@ucsf.edu
24863	NCT06028074	Tsai, Katy	A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies	Treatment	sonia.contrerasmartinez@ucsf.edu
23852	NCT03589339	Chan, Jason	A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With An Anti-PD-1 Therapy	Treatment	sonia.contrerasmartinez@ucsf.edu
22992	NCT05533697	Daud, Adil	Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors	Treatment	sonia.contrerasmartinez@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
23859	NCT06190951	Daud, Adil	A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPIMAB COMPARED WITH PEMBROLIZUMAB IN PATIENTS WITH RESECTABLE STAGE III AND IV MELANOMA	Treatment	sonia.contrerasmartinez@ucsf.edu
Cutaneous > Merkel Cell Carcinoma					
24865	NCT06947928	Daud, Adil	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint-Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma	Treatment	sonia.contrerasmartinez@ucsf.edu
Cutaneous > Melanoma > Locally Advanced/ Metastatic					
25709	NCT06946225	Daud, Adil	A first-in-human, open-label trial to evaluate the combination of ACTengine® IMA203 with mRNA-4203 in previously treated, unresectable or metastatic cutaneous melanoma or synovial sarcoma patients (ACTengine® IMA203-102)	Treatment	Christina.Chun@ucsf.edu
Cutaneous > Melanoma > Immunotherapy					
18991	NCT03486873	Daud, Adil	A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial	Treatment	Adil.Daud@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gastrointestinal > Pancreatic Cancer					
23992	NCT06177171	Munster, Pamela	A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; savannah.berkley@ucsf.edu
Gastrointestinal > Neuroendocrine Tumors (NET)					
25953	NCT06885281	Aggarwal, Rahul	A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors	Treatment	1-877-827-3222
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	1-877-827-3222
Gastrointestinal > Colon Cancer					
234513	NCT05419011	Singh, Aparajita	A PHASE IIB CLINICAL TRIAL OF THE MULTITARGETED RECOMBINANT ADENOVIRUS 5 (CEA/MUC1/BRACHYURY) VACCINES (TRI-AD5) AND IL-15 SUPERAGONIST N-803 IN LYNCH SYNDROME	Prevention	rachaelleigh.delacruz@ucsf.edu
Gastrointestinal > Rectal Cancer					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	erin.vanblarigan@ucsf.edu
Gastrointestinal > Esophageal and Gastric Cancer (including GE junction)					
25953	NCT06885281	Aggarwal, Rahul	A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors	Treatment	1-877-827-3222
Gastrointestinal > Biliary Tract Cancers (Cholangiocarcinoma)					
234510	NCT06160752	Kelley, Robin	A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors With Activating FGFR2 Gene Alterations (SURF-201)	Treatment	farhana.moon@ucsf.edu
244512	NCT06467357	Kelley, Robin	DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rivegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer	Treatment	farhana.moon@ucsf.edu
Gastrointestinal > Colon Cancer > Resectable					
NRG-GI008	NCT05174169	Eftimie, Bogdan	NRG-GI008: COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)	Treatment	Bogdan.Eftimie@ucsf.edu
Gastrointestinal > Colon Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
25703	NCT06778863	Oh, David	GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Treatment	Christina.Chun@ucsf.edu; allyson.beaulieu@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gastrointestinal > Rectal Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	1-877-827-3222
Gastrointestinal > Esophageal and Gastric Cancer (including GE junction) > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	1-877-827-3222
Gastrointestinal > Biliary Tract Cancers (Cholangiocarcinoma) > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	1-877-827-3222
Gastrointestinal > Colon Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	1-877-827-3222
Gastrointestinal > Gastrointestinal Stromal Tumor (GIST) > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	1-877-827-3222
Gastrointestinal > Anal Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic)					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	1-877-827-3222
Gastrointestinal > Pancreatic Cancer > Metastatic					
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	1-877-827-3222
21951	NCT04939610	Ko, Andrew	LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gastrointestinal > Hepatocellular Carcinoma (liver cancer) > Metastatic/Advanced					
244519	NCT06915753	Kelley, Robin	A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations (SURF431)	Treatment	Ronnie.Padilla@ucsf.edu; farhana.moon@ucsf.edu
19721	NCT04221893	Feng, Mary	Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy (ARM-GI)	Treatment	1-877-827-3222
Gastrointestinal > Anal Cancer > Localized > HIV Positive					
AMC-110	NCT04929028	Wang, Chia-Ching	Risk-adapted therapy for HIV-associated anal cancer	Treatment	Paul.Couey@ucsf.edu
Gastrointestinal > Colon Cancer > Resectable > Adjuvant (after surgery)					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	erin.vanblarigan@ucsf.edu
Gastrointestinal > Hepatocellular Carcinoma (liver cancer) > Metastatic/Advanced > First-Line					
204517	NCT04524871	Kelley, Robin	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	Treatment	farhana.moon@ucsf.edu
Gastrointestinal > Pancreatic Cancer > Metastatic > Second-Line and Beyond					
ALLIANCE-A022106	NCT06115499	Ko, Andrew	Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)	Treatment	Dalila.Stanfield@ucsf.edu; kevin.lopez@ucsf.edu
Gastrointestinal > Colon Cancer > Advanced (including Locally Advanced / Inoperable and Metastatic) > Second-Line and Beyond					
22705	NCT05319314	Keenan, Bridget	A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer	Treatment	Christina.Chun@ucsf.edu
Gastrointestinal > Pancreatic Cancer > Metastatic > Second-Line and Beyond					
25703	NCT06778863	Oh, David	GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Treatment	Christina.Chun@ucsf.edu; allyson.beaulieu@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Genitourinary > Bladder Cancer					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	erin.vanblarigan@ucsf.edu
Genitourinary > Prostate Cancer					
23992	NCT06177171	Munster, Pamela	A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; savannah.berkley@ucsf.edu
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	erin.vanblarigan@ucsf.edu
NRG-GU008	NCT04134260	Seyedin, Steven	RANDOMIZED PHASE III TRIAL INCORPORATING APALUTAMIDE AND ADVANCED IMAGING INTO SALVAGE TREATMENT FOR PATIENTS WITH NODE-POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY	Treatment	1-877-827-3222
24721	NCT05939414	Seyedin, Steven	An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)	Treatment	1-877-827-3222
20553	NCT04763980	Kwon, Daniel	Navigate Study: use of a community-based Health Coach to improve access to germline genetic testing among African American men with prostate cancer	Health Services Research	1-877-827-3222
22554	NCT05396872	Kwon, Daniel	A Multi-Stage Study to Improve Informed Decision-Making for Precision Oncology in Veterans with Advanced Prostate Cancer	Health Services Research	1-877-827-3222
Genitourinary > Renal Cell Carcinoma					
18525	NCT04258462	Wang, Jane Zhen	Hyperpolarized 13C pyruvate metabolic MRI to predict renal tumor aggressiveness	Diagnostic	1-877-827-3222
25522	NCT07049926	Desai, Arpita	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy	Treatment	GUtrials@ucsf.edu; lauren.trihy@ucsf.edu
NRG-GU012	NCT05327686	Seyedin, Steven	NRG-GU012: RANDOMIZED PHASE II STEREOTACTIC ABLATIVE RADIATION THERAPY (SABR) FOR METASTATIC UNRESECTED RENAL CELL CARCINOMA (RCC) RECEIVING IMMUNOTHERAPY (SAMURAI)	Treatment	1-877-827-3222
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	erin.vanblarigan@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Genitourinary > Testicular Cancer					
AGCT1531	NCT03067181	Rangaswami, Arun	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Treatment	karina.wong@ucsf.edu; maria.ponsventura@ucsf.edu; nicole.elzie-tuttle@ucsf.edu
Genitourinary > Bladder Cancer > Localized / Muscle Invasive					
23522	NCT05911295	Koshkin, Vadim	An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)	Treatment	GUtrials@ucsf.edu
24522	NCT06470282	Koshkin, Vadim	EV-PRIME: Phase Ib/II Study of Enfortumab Vedotin and Pembrolizumab Combined with Radiotherapy as a Bladder-Sparing Trimodality Therapy in Muscle Invasive Bladder Cancer	Treatment	GUtrials@ucsf.edu
Genitourinary > Bladder Cancer > Metastatic					
24523	NCT06225596	Friedlander, Terence	A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	Treatment	GUtrials@ucsf.edu; lisa.kody@ucsf.edu
23522	NCT05911295	Koshkin, Vadim	An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)	Treatment	GUtrials@ucsf.edu
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC)					
245519	NCT06691984	Aggarwal, Rahul	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy	Treatment	GUtrials@ucsf.edu
25703	NCT06778863	Oh, David	GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Treatment	Christina.Chun@ucsf.edu; allyson.beaulieu@ucsf.edu
24558	NCT06318273	Aggarwal, Rahul	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer	Treatment	GUtrials@ucsf.edu; daniel.avins@ucsf.edu
23921	NCT05888532	Aggarwal, Rahul	A First-in-Human, Phase I/II PET imaging Study of ⁶⁴ Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients with Advanced Malignancies	Diagnostic	maya.aslam@ucsf.edu
245513	NCT06551324	De Kouchkovsky, Ivan	A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)	Treatment	GUtrials@ucsf.edu; lisa.kody@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Genitourinary > Prostate Cancer > Localized > Pre-Therapy / Neoadjuvant					
15557	NCT02526368	De Kouchkovsky, Ivan	A Pilot Study of Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer	Diagnostic	1-877-827-3222
18702	NCT03821246	Oh, David	An open-label multi-center phase II study of neoadjuvant atezolizumab-based combination therapy in men with localized prostate cancer prior to radical prostatectomy	Treatment	1-877-827-3222
235513	NCT06384222	De Kouchkovsky, Ivan	Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) as a Response Monitoring Tool in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy	Treatment	1-877-827-3222
25922	NCT07054346	Hope, Thomas	Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 in a Prostatectomy Model (LUTACT Trial)	Treatment	louise.magat@ucsf.edu
Genitourinary > Prostate Cancer > Localized > Adjuvant					
175516	NCT03933670	De Kouchkovsky, Ivan	A Phase 2 Study of Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) in Patients with Prostate Cancer on Active Surveillance	Diagnostic	1-877-827-3222
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Naïve - AR Target Therapy Resistant					
235511	NCT06228053	Fitzgerald, Kelly	A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial	Treatment	GUtrials@ucsf.edu
21556	NCT04986423	Aggarwal, Rahul	A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer	Treatment	1-877-827-3222
23551	NCT05766371	Aggarwal, Rahul	A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients with Metastatic Castration Resistant Prostate Cancer	Treatment	GUtrials@ucsf.edu; medini.rastogi@ucsf.edu
Genitourinary > Bladder Cancer > Metastatic > Prior Chemotherapy					
22524	NCT04879329	Koshkin, Vadim	A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2	Treatment	1-877-827-3222
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Naïve - AR Target Therapy Resistant					
245516	NCT06842498	Aggarwal, Rahul	A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients with Metastatic Castration-Resistant Prostate Cancer	Treatment	GUtrials@ucsf.edu; lauren.trihy@ucsf.edu
Genitourinary > Prostate Cancer > Localized > Adjuvant					
24922	NCT06391034	Bok, Robert	A Phase 2 Study of Magnetic Resonance (MR) Imaging with Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients with Prostate Cancer Undergoing Radiation Therapy	Diagnostic	louise.magat@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Genitourinary > Bladder Cancer > Metastatic > Prior Chemotherapy and/or Prior Immunotherapy					
24527	NCT05929235	Friedlander, Terence	A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma	Treatment	GUtials@ucsf.edu
Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Resistant					
23923	NCT05924672	Hope, Thomas	Efficacy of Ra-223 in PSMA PET Optimally Selected Patients	Treatment	1-877-827-3222
25924	NCT06526299	Hope, Thomas	A Phase 2 study of biomarker-modulated PSMA theranostics	Treatment	elizabeth.milton@ucsf.edu; maya.aslam@ucsf.edu
Genitourinary > Bladder Cancer > Metastatic > Prior Chemotherapy and/or Prior Immunotherapy					
25703	NCT06778863	Oh, David	GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Treatment	Christina.Chun@ucsf.edu; allyson.beaulieu@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	erin.vanblarigan@ucsf.edu
24407	NCT06619236	Alvarez, Edwin	A Phase 3 Randomized, Open-label Study of Rinabart Sesutecan (Rina-S) versus Treatment of Investigator's Choice (IC) in Patients with Platinum Resistant Ovarian Cancer	Treatment	Nathalie.Halley2@ucsf.edu
224010	NCT04606914	Chapman, Jocelyn	Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor alpha positive	Treatment	Nathalie.Halley2@ucsf.edu
Gynecological > Corpus/Endometrial					
21456	NCT05056077	Van Blarigan, Erin	Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)	Supportive Care	erin.vanblarigan@ucsf.edu
244010	NCT06463028	Alvarez, Edwin	An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel plus an Insulin-Suppressing Diet, in Patients with Advanced or Recurrent Endometrial Cancer	Treatment	Nathalie.Halley2@ucsf.edu; Ronnie.Padilla@ucsf.edu
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > First Line					
AGCT1531	NCT03067181	Rangaswami, Arun	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Treatment	karina.wong@ucsf.edu; maria.ponsventura@ucsf.edu; nicole.elzie-tuttle@ucsf.edu
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > Progressive/Recurrent					
25703	NCT06778863	Oh, David	GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Treatment	Christina.Chun@ucsf.edu; allyson.beaulieu@ucsf.edu
Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > BRCA					
23992	NCT06177171	Munster, Pamela	A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; savannah.berkley@ucsf.edu
Gynecological > Corpus/Endometrial > Rare Tumor					
244013	NCT06809933	Cham, Stephanie	EMPOWER: Exercise and Movement to Promote Our patients With (gynecologic) cancer to Enhance Resiliency	Supportive Care	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx)					
23203	NCT06097468	Yom, Sue	A Phase I/IIa, Single-Arm, Dose-Confirmation and Dose-Expansion Study Evaluating Changes in the Oral Microbiome of Patients with Oral Cavity Squamous Cell Carcinoma (OSCC) after Short-Term Ingestion of Nisin, a Naturally Occurring Food Preservative	Treatment	arielle.oglesby@ucsf.edu
22721	NCT05273307	Yom, Sue	Addressing taste dysfunction with miraculin in head and neck cancer patients receiving radiation therapy: A double-blinded, placebo-controlled, randomized phase III trial	Supportive Care	1-877-827-3222
25703	NCT06778863	Oh, David	GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Treatment	Christina.Chun@ucsf.edu; allyson.beaulieu@ucsf.edu
Head and Neck > Adenoid Cystic / Salivary					
NRG-HN010	NCT05408845	Algazi, Alain	NRG-HN010: A PHASE II TRIAL OF HER2-TARGETED THERAPIES FOR RECURRENT, METASTATIC, OR UNRESECTABLE HER2-EXPRESSING SALIVARY GLAND CANCERS	Treatment	arielle.oglesby@ucsf.edu
22721	NCT05273307	Yom, Sue	Addressing taste dysfunction with miraculin in head and neck cancer patients receiving radiation therapy: A double-blinded, placebo-controlled, randomized phase III trial	Supportive Care	1-877-827-3222
21728	NCT04883671	Yom, Sue	Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR trial	Treatment	1-877-827-3222
Head and Neck > Thyroid					
249212	NCT06961084	Hope, Thomas	Comparison of I-124 PET/CT to I-123 whole body imaging for the diagnosis of thyroid cancer	Diagnostic	maya.aslam@ucsf.edu
Head and Neck > Nasopharyngeal					
24726	NCT06682442	Yom, Sue	Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma	Treatment	1-877-827-3222
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Metastatic					
24951	NCT06118086	Algazi, Alain	A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma	Treatment	1-877-827-3222
24203	NCT06496178	Algazi, Alain	A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma	Treatment	arielle.oglesby@ucsf.edu
Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Locoregional > No Prior Therapy > Peri Operative					
177018	NCT03708224	Algazi, Alain	A Phase II Study of Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Acute Myeloid Leukemia (AML)					
ECOG-ACRIN-MM10A-EA02	NCT06317649	Ferng, Timothy	A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial	Treatment	1-877-827-3222
SWOG-MM1YA-S01	NCT05554406	Ferng, Timothy	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial	Treatment	1-877-827-3222
242522	NCT06001788	Ferng, Timothy	Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia	Treatment	1-877-827-3222
172521	NCT03013998	Olin, Rebecca	A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)	Treatment	1-877-827-3222
SWOG-MYELOMATCH	NCT05564390	Ferng, Timothy	Master Screening and Reassessment Protocol (MSRP) For Tier Advancement In The NCI Myelomatch Clinical Trials	Screening	1-877-827-3222
242526	NCT06578247	Ferng, Timothy	A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia	Treatment	Samantha.Zylberman@ucsf.edu
Malignant Hematology > T-Cell Lymphoma					
SWOG-S2114	NCT05633615	Seshadri, Madhav	A RANDOMIZED PHASE II TRIAL OF CONSOLIDATION THERAPY FOLLOWING CD19 CAR T-CELL TREATMENT FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA OR GRADE IIIB FOLLICULAR LYMPHOMA	Treatment	Samantha.Zylberman@ucsf.edu
212531	NCT05351593	Rubenstein, James	A Phase I/II Study of Tafasitamab plus Lenalidomide in Relapsed CNS Lymphoma	Treatment	1-877-827-3222
Malignant Hematology > Blood and Marrow Transplant (BMT)					
25257	NCT06938867	Doernberg, Sarah	A Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients with Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia coli Pre-Transplant	Prevention	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Non-Hodgkin Lymphoma (NHL)					
ALLIANCE-A051901	NCT04609046	Rubenstein, James	Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma	Treatment	1-877-827-3222
242523	NCT06500273	Spinner, Michael	A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma	Treatment	Samantha.Zylberman@ucsf.edu
22706	NCT05169515	Andreadis, Charalambos	A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND/OR CC-99282 IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA	Treatment	1-877-827-3222
16252	NCT02445222	Andreadis, Charalambos	Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy	Other	1-877-827-3222
237011	NCT06028373	Keenan, Bridget	A First-in-Human Phase I Study of ATG-031 in Patients with Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas	Treatment	1-877-827-3222
20924	NCT04656431	Rubenstein, James	Pilot Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients with Primary CNS Lymphoma	Diagnostic	James.Rubenstein@ucsf.edu; Wendy.Ma@ucsf.edu
24923	NCT06522932	Randall, Michael	A Phase I/Ib PET imaging Study of ⁶⁴ Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients Receiving CD19-directed CAR-T Therapy	Diagnostic	1-877-827-3222
242518	NCT06561048	Ai, Weiyun	A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma	Treatment	essence.fisherhobson@ucsf.edu
22256	NCT04077723	Andreadis, Charalambos	AN OPEN-LABEL, PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF ENGLUMAFUSP ALFA (RO7227166, A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH OBINUTUZUMAB AND IN COMBINATION WITH GLOFITAMAB FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Multiple Myeloma (MM)					
23925	NCT05892393	Flavell, Robert	Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma	Diagnostic	maya.aslam@ucsf.edu
24253	NCT05257083	Chung, Alfred	A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible	Treatment	Samantha.Zylberman@ucsf.edu; claudia.ramos@ucsf.edu
24258	NCT06577025	Pan, Darren	A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC (Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple Myeloma	Treatment	Samantha.Zylberman@ucsf.edu; charles.sydnor@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory					
242521	NCT04973605	Lipof, Jodi	A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)	Treatment	1-877-827-3222
212536	NCT05201781	Martin, Tom	Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel	Other	jungeun.kim@ucsf.edu
Malignant Hematology > T-Cell Lymphoma > Relapsed/Refractory					
23258	NCT05131022	Rubenstein, James	A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degradar, in Adults With Relapsed/Refractory B-cell Malignancies	Treatment	1-877-827-3222
Malignant Hematology > Acute Myeloid Leukemia (AML) > Relapsed / Refractory					
APAL2020SC	NCT04726241	Stieglitz, Elliot	Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias	Screening	karina.wong@ucsf.edu; nicole.elzie-tuttle@ucsf.edu; shani.lyubomirsky@ucsf.edu
Malignant Hematology > Acute Lymphoblastic Leukemia (ALL) > Relapsed / Refractory					
APAL2020SC	NCT04726241	Stieglitz, Elliot	Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias	Screening	karina.wong@ucsf.edu; nicole.elzie-tuttle@ucsf.edu; shani.lyubomirsky@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Malignant Hematology > Acute Myeloid Leukemia (AML) > Relapsed / Refractory					
212524	NCT04811560	Ferng, Timothy	A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia (cAMELot-1)	Treatment	jungeun.kim@ucsf.edu; karina.wong@ucsf.edu; nicole.elzie-tuttle@ucsf.edu
Malignant Hematology > Acute Lymphoblastic Leukemia (ALL) > Relapsed / Refractory					
212524	NCT04811560	Ferng, Timothy	A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia (cAMELot-1)	Treatment	jungeun.kim@ucsf.edu; karina.wong@ucsf.edu; nicole.elzie-tuttle@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory > 1-3 Prior Lines of Therapy					
232514	NCT06348108	Chung, Alfred	A Phase Ib, Multi-center, Study of Talquetamab in Combination with Ibrdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma	Treatment	Nickole.criner@ucsf.edu; charles.sydnor@ucsf.edu
Malignant Hematology > Multiple Myeloma (MM) > Relapsed / Refractory > 3 or More Prior Lines of Therapy					
24251	NCT06297226	Kumar, Anupama	A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)	Treatment	charles.sydnor@ucsf.edu
25702	NCT05850234	Kumar, Anupama	A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma	Treatment	Christina.Chun@ucsf.edu; allyson.beaulieu@ucsf.edu
25707		Martin, Tom	A Phase 1b Clinical Trial of CRISPR Delivered Anti-BCMA Chimeric Antigen Receptor T cells for Treatment of Relapsed or Refractory Multiple Myeloma	Treatment	1-877-827-3222
23951	NCT05651932	Chung, Alfred	A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma	Treatment	savannah.berkley@ucsf.edu
Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Negative > Relapsed / Refractory > Aggressive					
232516	NCT06252675	Seshadri, Madhav	A Multicenter Phase 2 Study of Glofitamab with Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Multiple / III-Defined Disease Sites > Solid Tumors					
22951	NCT05094336	Munster, Pamela	A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors	Treatment	cindy.zhang@ucsf.edu
249214	NCT06942104	Aggarwal, Rahul	Imaging of Solid Tumors Using 18F-TRX	Diagnostic	1-877-827-3222
21708	NCT04626635	Keenan, Bridget	A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors	Treatment	1-877-827-3222
22801	NCT05297734	Dixit, Niharika	Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults with Cancer	Supportive Care	1-877-827-3222
25957	NCT05919264	Monga, Varun	A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors	Treatment	1-877-827-3222
25704	NCT06952010	Fitzgerald, Kelly	A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors	Treatment	1-877-827-3222
AMC-107	NCT04305691	Wang, Chia-Ching	A Phase 2 Trial of Ixazomib for Kaposi Sarcoma	Treatment	1-877-827-3222
237011	NCT06028373	Keenan, Bridget	A First-in-Human Phase I Study of ATG-031 in Patients with Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas	Treatment	1-877-827-3222
229510	NCT05694715	Munster, Pamela	Combination Therapy of Niraparib and Irinotecan in Cancers with Mutations in DNA Repair Genes	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; kelsey.cordero@ucsf.edu
23992	NCT06177171	Munster, Pamela	A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors	Treatment	EarlyPhaseClinicalTrials@ucsf.edu; savannah.berkley@ucsf.edu
25921	NCT06894745	Flavell, Robert	Positron Emission Tomography (PET) Imaging of the Enhanced Permeability and Retention (EPR) Effect with [89Zr]DFO-starPEG in Patients with Solid Tumors	Diagnostic	maya.aslam@ucsf.edu
21951	NCT04939610	Ko, Andrew	LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor	Treatment	1-877-827-3222
189510	NCT03682289	Aggarwal, Rahul	Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination with Olaparib or Durvalumab in Patients with Selected Solid Tumor Malignancies	Treatment	1-877-827-3222
25952	NCT06723236	Munster, Pamela	A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants with Advanced Solid Tumors	Treatment	zach.schoenherr@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
247012	NCT06276491	Aggarwal, Rahul	A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors	Treatment	1-877-827-3222
20929	NCT04621435	Hope, Thomas	Imaging of Solid Tumors Using FAP-2286	Diagnostic	brad.kline@ucsf.edu; maya.aslam@ucsf.edu
22924	NCT05599048	Bok, Robert	A Phase I/II Study of Hyperpolarized ¹³ C MRI as a Biomarker of Aggressiveness & Response to Therapy in Patients with Advanced Solid Tumors	Diagnostic	louise.magat@ucsf.edu
23953	NCT05768139	Munster, Pamela	First-in-Human Study of STX-478, a Mutant-Selective PI3Kalpha Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors	Treatment	cherilyn.yu@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Neurologic Oncology > Adult Glioma (Age >= 18)					
13106	NCT03739411	Chang, Susan	Pilot Study of Safety and Feasibility of Acquiring Hyperpolarized Imaging in Patients with Gliomas	Diagnostic	Jane.Rabbitt@ucsf.edu
23102	NCT05503797	Butowski, Nicholas	A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations	Treatment	1-877-827-3222
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 2 (Low Grade)					
19103	NCT03948490	Taylor, Jennie	Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas	Supportive Care	karishma.kumar@ucsf.edu
Neurologic Oncology > Adult Brain Tumors, Other (Non-Glioma) > Meningioma					
23924	NCT06014905	Villanueva-Meyer, Javier	Pilot/Phase I study of feasibility of acquiring hyperpolarized imaging in patients with meningioma	Diagnostic	Alya.Briceno@ucsf.edu; Wendy.Ma@ucsf.edu; Xin.Mu@ucsf.edu
24724	NCT06557512	Chen, William	A Pilot trial of adjuvant hypofractionated stereotactic radiosurgery for intermediate-risk meningioma (SRS-AIM)	Treatment	1-877-827-3222
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 4 (Glioblastoma or Gliosarcoma)					
221022	NCT05484622	Clarke, Jennifer	A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive IDH-1 Mutant Glioma	Treatment	1-877-827-3222
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 4 (Glioblastoma or Gliosarcoma) > Newly diagnosed > Surgical					
231017	NCT06504381	Butowski, Nicholas	A Phase I/IIa Study to Evaluate the Efficacy of DB107-RRV (Formerly Toca 511), Administered to Subjects at Time of Resection and Intravenously Thereafter, in Combination with DB107-FC (Formerly Toca FC) and Radiation Therapy or DB107-FC, Temozolomide (TMZ) and Radiation Therapy in Patients with Newly Diagnosed High Grade Glioma	Treatment	Christian.Gonzalez-Gomez@ucsf.edu
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 4 (Glioblastoma or Gliosarcoma) > Recurrent > Surgical					
24104	NCT06069726	de Groot, John	A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial	Treatment	1-877-827-3222
Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 4 (Glioblastoma or Gliosarcoma) > Newly diagnosed > Nonsurgical					
231010	NCT05708352	Butowski, Nicholas	A randomized controlled phase 2 study of the ketogenic diet versus standard dietary guidance for patients with newly diagnosed glioblastoma in combination with standard-of-care treatment	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Thoracic > Non-small cell Lung Cancer					
25953	NCT06885281	Aggarwal, Rahul	A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors	Treatment	1-877-827-3222
Thoracic > Small cell Lung Cancer					
25655	NCT06788938	Mulvey, Claire	Tarlatamab in Advanced DLL3-Expressing Tumors Including Neuroendocrine Neoplasms	Treatment	lisa.tan@ucsf.edu
25703	NCT06778863	Oh, David	GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Treatment	Christina.Chun@ucsf.edu; allyson.beaulieu@ucsf.edu
25923	NCT06736418	Mulvey, Claire	A PHASE 1A/B, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND INITIAL EFFICACY OF 225AC-ABD147 IN PATIENTS WITH SMALL CELL LUNG CANCER AND LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG FOLLOWING PLATINUM-BASED CHEMOTHERAPY	Treatment	maya.aslam@ucsf.edu
22658	NCT05595460	Mulvey, Claire	Phase 1b single arm, open-label trial of RYZ101 in combination with carboplatin + etoposide + atezolizumab in subjects with somatostatin receptor expressing (SSTR+) extensive stage small cell lung cancer (ES-SCLC)	Treatment	lisa.tan@ucsf.edu
Thoracic > Mesothelioma					
246511	NCT04665206	Monga, Varun	Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients with Locally Advanced or Metastatic Solid Tumors	Treatment	1-877-827-3222
Thoracic > Sarcoma					
24872	NCT05712694	Monga, Varun	ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial	Treatment	lisa.tan@ucsf.edu
ECOG-ACRIN-EA7222	NCT06422806	Monga, Varun	A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas	Treatment	1-877-827-3222
24871	NCT03715933	Monga, Varun	An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas	Treatment	lisa.tan@ucsf.edu
25957	NCT05919264	Monga, Varun	A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid Tumors	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
Thoracic > Non-small cell Lung Cancer > By Mutation or Histology					
24651	NCT06162221	Cheng, Michael	A Platform Study of RAS(ON) Inhibitors in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)	Treatment	lisa.tan@ucsf.edu
246512	NCT06452277	Cheng, Michael	A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations	Treatment	1-877-827-3222
Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > EGFR (epidermal growth factor receptor) Mutation					
24325	NCT06667076	Velazquez Manana, Ana	A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Treatment	Paul.Couey@ucsf.edu; ivan.leung@ucsf.edu
Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > KRAS Mutation					
25657	NCT06343402	Cheng, Michael	A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study	Treatment	lisa.tan@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
her Trials					
EA-JCAR017-001-ANDREADIS	NCT04400591	Andreadis, Charalambos	EXPANDED ACCESS PROTOCOL (EAP) FOR PATIENTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE	Other	1-877-827-3222
23456	NCT05968326	Ko, Andrew	A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA	Treatment	kevin.lopez@ucsf.edu; luke.getchell@ucsf.edu
ALLIANCE-A222004	NCT04939090	Dixit, Niharika	A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED ANOREXIA	Supportive Care	Paul.Couey@ucsf.edu
24632	NCT06432985	Herbst, Ellen	Contingency Management For Veteran Smokers With or at Risk for Cancer	Prevention	ellen.herbst@ucsf.edu
25751	NCT06435429	Batra-Sharma, Hemali	A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment	Treatment	Amy.Deluca@ucsf.edu
18863	NCT03767348	Tsai, Katy	An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors	Treatment	sonia.contrerasmartinez@ucsf.edu
230827	NCT05533775	Michlitsch, Jennifer	A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma	Treatment	teran.nieman@ucsf.edu
23702	NCT04471727	Aggarwal, Rahul	A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and, HPN328 with Atezolizumab or Ifinatumab Deruxtecan (I-DXd) in Patients with Advanced Cancers Associated with Expression of Delta-like Canonical Notch Ligand 3 (DLL3)	Treatment	1-877-827-3222
ARST2032-T	NCT05304585	Michlitsch, Jennifer	A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma: A COG Groupwide Phase 3 Study	Treatment	teran.nieman@ucsf.edu
AOST2032-T	NCT05691478	Michlitsch, Jennifer	AOST2032: A feasibility and randomized phase 2/3 study of VEGFR2/MET inhibitor cabozantinib in combination with cytotoxic chemotherapy for newly diagnosed osteosarcoma: an intergroup NCTN phase 3 study	Treatment	1-877-827-3222
24956	NCT06244771	Munster, Pamela	An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors	Treatment	rachel.sanyu@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
249210	NCT06235151	Nguyen, Hao	A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection	Diagnostic	Imelda.Tenggara@ucsf.edu
RTOG-1216	NCT01810913	Chan, Jason	Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck	Treatment	1-877-827-3222
177017	NCT03435796	Kumar, Anupama	LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH CAR T CELLS	Other	1-877-827-3222
21259	NCT04771078	Kumar, Anupama	Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release	Other	roz.ruiz@ucsf.edu
SWOG-S1827	NCT04155034	Wang, Sunny	MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer	Treatment	1-877-827-3222
21636	NCT04627922	Herbst, Ellen	N-Acetylcysteine for Smoking Cessation in Cigarette-Cannabis Co-Users: A Randomized Controlled Trial	Prevention	1-877-827-3222
240816	NCT05489887	Michlitsch, Jennifer	A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma	Treatment	nicole.elzie-tuttle@ucsf.edu; teran.nieman@ucsf.edu
229511	NCT05315700	Cheng, Michael	An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration	Treatment	lisa.tan@ucsf.edu
23952	NCT05107674	Munster, Pamela	A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types	Treatment	1-877-827-3222
23704	NCT06186401	Clarke, Jennifer	Phase 1 Study of Autologous anti-EGFRvIII synNotch Receptor Induced anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells in Adult Participants with EGFRvIII+ Glioblastoma	Treatment	Christina.Chun@ucsf.edu; abigail.hansen@ucsf.edu
ANHL2121-T	NCT05828069	Michlitsch, Jennifer	Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis	Treatment	teran.nieman@ucsf.edu
24702	NCT06153251	Chung, Alfred	A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants with Relapsed and/or Refractory Multiple Myeloma	Treatment	Christina.Chun@ucsf.edu
24926	NCT06630845	Hope, Thomas	Comparison of Whole Body DWI to FDG PET using PET/MRI	Diagnostic	brad.kline@ucsf.edu; louise.magat@ucsf.edu; sophia.millet@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
249515	NCT06645886	Shah, Neil	A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hematologic Malignancies	Treatment	1-877-827-3222
24058	NCT05673018	Tempero, Margaret	REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity	Screening	1-877-827-3222
CCTG-MM1YA-CTG01	NCT05554393	Ferng, Timothy	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	Treatment	1-877-827-3222
228011-EXTNARM	NCT05421689	Rosen, Clark	A Multi-Center, Double-Blind, Randomized Placebo-Controlled Investigation of Autologous Muscle Derived Cells (AMDC) for the Treatment of Tongue Dysphagia Resulting from the Treatment of Head and Neck Cancer (REVIVE)	Supportive Care	1-877-827-3222
16751	NCT03011684	Rosen, Mitchell	Fertility Preservation Using Tamoxifen or Letrozole in Estrogen Sensitive Tumors Trial (TALES Trial)	Supportive Care	Flor.Juarez-Hernandez@ucsf.edu
20922	NCT04346225	De Kouchkovsky, Ivan	Magnetic Resonance (MR) Imaging with Hyperpolarized Pyruvate (13C) as a Diagnostic and Response Monitoring Imaging Tool in Advanced Prostate Cancer	Diagnostic	1-877-827-3222
19089	NCT03509961	Higham, Christine	A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative	Treatment	magruderk@radonc.ucsf.edu
24088	NCT04301843	Michlitsch, Jennifer	Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma	Treatment	nicole.elzie-tuttle@ucsf.edu
19703	NCT04545762	Ho, Carrie	A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	Treatment	1-877-827-3222
AGCT1531-T	NCT03067181	Michlitsch, Jennifer	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Treatment	Sheila.Contapay-Tabilin@ucsf.edu
AALL1621-T	NCT02981628	Michlitsch, Jennifer	A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)	Treatment	Sheila.Contapay-Tabilin@ucsf.edu
21457	NCT05028725	Buckle, Geoffrey	Investigation of a Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma	Diagnostic	1-877-827-3222
ALLIANCE-A021901	NCT04665739	Mulvey, Claire	Randomized Phase II Trial of Lutetium Lu177 DOTATATE Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
230826	NCT04696029	Hastings, Caroline	Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma	Treatment	1-877-827-3222
24921	NCT06074510	Carroll, Peter	A Phase 4 Open-Label Multicenter Study of PYLARIFY® PET/CT or PET/MRI in Men with Newly Diagnosed Favorable Intermediate Risk (FIR) Prostate Cancer	Diagnostic	1-877-827-3222
ACNS1821-T	NCT05099003	Hastings, Caroline	A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)	Treatment	1-877-827-3222
24953	NCT05838768	Munster, Pamela	An Open-label, Multi-center Phase I/Ib Dose Finding and Expansion Study of HRO761 as Single Agent and in Combinations in Patients With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors.	Treatment	rachel.sanyu@ucsf.edu
249516	NCT06545942	Aggarwal, Rahul	A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors	Treatment	1-877-827-3222
ARAR2221-T	NCT06064097	Michlitsch, Jennifer	A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)	Treatment	1-877-827-3222
25632	NCT07148232	Vijayaraghavan, Maya	Extended Intervention for Tobacco (EXIT) use for people experiencing homelessness	Prevention	1-877-827-3222
25802	NCT07165600	Piawah, Sorbarikor	Yoga to Improve Disparities in Cancer Survivorship	Supportive Care	1-877-827-3222
161016	NCT04540107	Chang, Susan	Metabolic Imaging of Patients with Lower Grade Glioma using Hyperpolarized 13C Pyruvate	Diagnostic	Wendy.Ma@ucsf.edu
SWOG-LUNGMAP	NCT03851445	Eftimie, Bogdan	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	Other	1-877-827-3222
ALLIANCE--A151216	NCT02194738	Wang, Sunny	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)	Screening	1-877-827-3222
21751	NCT05456373	Wong, Jasmine	Intraoperative Use of ClearEdge Device in Breast Conserving Surgery	Treatment	1-877-827-3222
215510	NCT05113537	Koshkin, Vadim	Phase I/II Study of CDK4/6 Inhibition with Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents.	Treatment	GUtrials@ucsf.edu
221017	NCT05303467	Butowski, Nicholas	FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere Glioblastoma (GBM) Device in PaTIENTs With Recurrent GBM	Treatment	1-877-827-3222
226311	NCT06213532	Walsh, Judith	CONNECTing to LungCare	Prevention	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
EA-MARTIN-05092023	NCT05346835	Lipof, Jodi	Expanded Access: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma	Other	1-877-827-3222
SWOG-LUNGMAP-S1900G	NCT05642572	Wang, Sunny	Lung-MAP: S1900G, A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)	Treatment	1-877-827-3222
23708	NCT05882058	Keenan, Bridget	DAREON-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas	Treatment	1-877-827-3222
ACCL1931-T	NCT05602194	Michlitsch, Jennifer	ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy	Supportive Care	1-877-827-3222
25253	NCT06911502	Andreadis, Charalambos	A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants with Relapsed/Refractory Follicular Lymphoma	Treatment	1-877-827-3222
194522	NCT04430452	Feng, Mary	Phase II Trial of Durvalumab (MEDI4736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Palliative Hypofractionated Radiotherapy	Treatment	1-877-827-3222
197021	NCT04221542	Aggarwal, Rahul	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer	Treatment	1-877-827-3222
19109	NCT04659811	Oberheim Bush, Nancy Ann	A Phase II Study of Stereotactic Radiosurgery in Conjunction with the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma	Treatment	karishma.kumar@ucsf.edu
24083	NCT02559778	Michlitsch, Jennifer	Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN): A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma	Treatment	nicole.elzie-tuttle@ucsf.edu
226310	NCT05829824	Tsoh, Janice	Connect Cancer Patients to Tobacco Cessation Care by Automated Interactive Outreach	Prevention	1-877-827-3222
228013	NCT05520866	Finlayson, Emily	PREHABPAL: A Digital Tool to Help Frail Elders Prepare for Cancer Surgery	Supportive Care	1-877-827-3222
23721	NCT05665738	Hsu, I-Chow	Two-fraction High Dose Rate Brachytherapy as Monotherapy Delivered Three Hours Apart in Localized Prostate Cancer: A Pilot Study	Treatment	david.haase2@ucsf.edu

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
24326	NCT06806033	Friedlander, Terence	A PHASE II, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE OPTIMIZATION OF THE CYTOKINE RELEASE SYNDROME PROFILE FOR GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGK'S LYMPHOMA	Treatment	Paul.Couey@ucsf.edu; ivan.leung@ucsf.edu
19108	NCT03970447	Butowski, Nicholas	GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)	Treatment	1-877-827-3222
24089	NCT02679144	Michlitsch, Jennifer	NMTT - Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)	Prevention	teran.nieman@ucsf.edu
AAML1831-T	NCT04293562	Michlitsch, Jennifer	A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations	Treatment	Sheila.Contapay- Tabilin@ucsf.edu
APAL2020SC-T	NCT04726241	Michlitsch, Jennifer	Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias	Screening	nicole.elzie-tuttle@ucsf.edu; teran.nieman@ucsf.edu
210813	NCT05478837	Mueller, Sabine	A Phase 1 Clinical Trial of Autologous T Cells Expressing a TCR Specific for H3.3K27M with Inhibition of Endogenous TCR (KIND T Cells) in HLA-A*0201-positive Participants with H3.3K27M-positive Diffuse Midline Gliomas	Treatment	elizabeth.horgan@ucsf.edu; nicole.elzie-tuttle@ucsf.edu
221014	NCT05557292	Butowski, Nicholas	A Phase I/Ib, Open-Label, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Recurrent Glioblastoma	Treatment	1-877-827-3222
221013	NCT05417594	Butowski, Nicholas	A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (CERTIS1)	Treatment	1-877-827-3222
AREN1921-T	NCT04322318	Michlitsch, Jennifer	Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)	Treatment	1-877-827-3222
234517	NCT06084234	Mehta, Neil	National Liver Cancer Screening Trial (TRACER)	Screening	1-877-827-3222
ECOG-ACRIN-EA5182	NCT04181060	Eftimie, Bogdan	Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)	Treatment	1-877-827-3222
AALL1732-T	NCT03959085	Michlitsch, Jennifer	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy	Treatment	1-877-827-3222

UCSF Protocol No.	ClinicalTrials.gov Protocol	PI Name	Title	Protocol Type	Study Contact
SWOG-S1918	NCT04799275	Ekstrand, Bradley	A PHASE II/III RANDOMIZED STUDY OF R-MINICHOP WITH OR WITHOUT CC-486 (ORAL AZACITIDINE) IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA, GRADE IIIB FOLLICULAR LYMPHOMA, TRANSFORMED LYMPHOMA, AND HIGH-GRADE B-CELL LYMPHOMAS WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS	Treatment	1-877-827-3222
22958	NCT05746208	Bergsland, Emily	A Phase II study of lenvatinib plus pembrolizumab in well differentiated G3 neuroendocrine tumors	Treatment	Sukjun.Lee@ucsf.edu
22925	NCT05851378	Chang, Susan	Hyperpolarized carbon-13 alpha-ketoglutarate metabolic imaging in IDH mutant glioma	Diagnostic	Xin.Mu@ucsf.edu
238012	NCT05403086	Anderson, Brian	Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life	Supportive Care	brian.anderson@ucsf.edu
232513	NCT06160791	Lee, Jerry	Frontline Ruxolitinib with De-Intensified HLH-94 for Adult Hemophagocytic Lymphohistiocytosis (HLH): A Multicenter, Single-Arm Phase 2 Study	Treatment	1-877-827-3222
24631	NCT06170437	Vijayaraghavan, Maya	Healthy Homes Study: A protocol for a place-based smoke-free home intervention in federally subsidized housing	Health Services Research	Maya.Vijayaraghavan@ucsf.edu
24955	NCT04855656	Aggarwal, Rahul	Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)	Treatment	1-877-827-3222
249512	NCT06265727	Munster, Pamela	A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients with Advanced Solid Tumors	Treatment	zach.schoenherr@ucsf.edu
24958	NCT06326411	Monga, Varun	A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors	Treatment	Sukjun.Lee@ucsf.edu
25956	NCT06993844	Munster, Pamela	A Phase 1/2, Open-Label, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-Mutant-Selective PI3Kalpha Inhibitor, as Monotherapy and in Combination with Other Anticancer Therapies in Participants with Advanced Solid Tumors	Treatment	1-877-827-3222